Extended-spectrum β-lactamases (ESBLs) are a group of plasmid-mediated, diverse, complex and
rapidly evolving enzymes that are posing a major therapeutic challenge today in the treatment of
hospitalized and community-based patients. Enterobacteriaceae group is the main cause of bacterial infection and in this
family Escherichia coli and Klebsiella species are the most common causes of nosocomial infections. ESBLs represents a major
threat among multidrug-resistant (MDR) bacteria isolates. These ESBL producing pathogens are now recognized globally as
major causes of nosocomial and community-acquired infections. ESBL detection is important from a therapeutic point of view
and for infection control purposes. Carbapenems are often used to treat infections caused by ESBL producing E. coli and
Klebsiella. This study was conducted in indoor patient department of Teerthanker Mahaveer Medical College & Research
Centre, Moradabad, U.P., which is a tertiary care hospital. This study was conducted during the period from April 2015 to
December 2017.A total no. of 350 gram negative Enterobacteriaceae were isolated in 800 no. of samples. They were screened
for the beta-lactamase production. Among the 350 isolates 210 strains were ESBL producers. The major ESBL producers were
E.coli (32%) followed by Klebsiella, Enterobacter, Citrobacter, Proteus. Multidrug resistance to Fluoroquinolones and
Aminoglycosides were observed in the ESBL producing organism. The most common ESBL producing organism were from ICU.